Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
10.499 / 17.032
#83987

Re: Farmas USA

Cabrón, que me has hecho ir a mirarla. ¿Y no será información privilegiada? XD

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#83989

Re: Farmas USA

ATHX

Del Bastardo, y tiene razón. Yo sigo creyendo en el potencial de sus células, pero los ensayos como ya dije en su día estaban mal hechos. Tendrán que volver a empezar y ahora toca dilución.

Let's unpack this: For starters, stroke is an acute illness requiring immediate medical intervention. A clinically meaningful outcome for stroke victims is improvement or recovery measured days or weeks after the stroke, not one year later.

Athersys used a "global test analysis" encompassing three different stroke-recovery measures -- the modified Rankin Scale (mRS), the NIH Stroke Scale and the Barthel Index -- to assess MultiStem's ability to improve recovery from a stroke after 90 days. On this measure, the study's primary efficacy endpoint, MultiStem was no different than placebo.

Secondarily, Athersys looked at each of the three stroke-recovery measures individually to detect a difference between MultiStem and placebo. The company found no difference.

Athersys defines "complete or nearly full recovery" as patients achieving an "excellent outcome," which is just a dumbed-down revision of the more stringent "global test analysis" measure used as the primary endpoint in the study. [The primary endpoint which MultiStem couldn't achieve last April].

After 90 days of follow-up -- the only time point that matters -- MultiStem also failed to demonstrate an improvement over placebo using the "excellent outcome" definition of stroke recovery. This just underscores its weakness: The stem cell therapy couldn't even muster a win over placebo using a remedial definition of stroke recovery.

http://www.thestreet.com/story/13464490/1/should-you-buy-into-athersys-rsquo-latest-spin-on-failed-stroke-therapy.html?puc=yahoo&cm_ven=YAHOO

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#83990

Re: Farmas USA

ADXS

Junta de accionistas el 10 de marzo

- Election of directors

- To approve an amendment to our Amended and Restated Certificate of Incorporation to increase our authorized shares of common stock by 20,000,000 shares from 45,000,000 to 65,000,000.

- To approve an amendment to our 2015 Incentive Plan to authorize an additional 1,000,000 shares thereunder.

- Consider and approve an advisory (non-binding) resolution regarding the compensation of our named executive officers.

- To ratify the selection of Marcum, LLP as our independent registered public accountants for the fiscal year ending October 31, 2016, which we refer to as fiscal 2016.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#83991

Re: Farmas USA

NVAX

Bueno, di por hecho lo que todos sabemos, que framus es el Rey de Reyes, y en la comparativa, todos mindundis, jajaja.

Te puede interesar...
  1. Primeras dudas sobre la 'Trumponomics', ¿corrección o toma de beneficios?
  2. Nvidia bate expectativas pero decepciona. Insiders reafirman su posición